Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study.
Shuu-Jiun WangByung-Kun KimHebo WangJiying ZhouQi WanTingmin YuYajun LianMichal ArkuszewskiLaurent EcochardJosefin SnellmanShihua WenFangfang YinZheng LiWendy SuSheng-Yuan YuPublished in: Headache (2024)
This analysis demonstrated that a greater proportion of patients treated with erenumab reverted from CM to EM compared to patients treated with placebo. The reversion from CM to EM was reflected by the greater improvements in patient-reported outcomes in the erenumab group.